The Hoffman ALS Clinical Trial Awards Program

The Hoffman ALS Clinical Trial Awards Program is sponsored by The ALS Association. Aims to develop new and improved therapies by supporting early-stage clinical trials.

Deadline Extended: Hoffman ALS Clinical Trial Awards - Health Research Alliance Deadline Extended: Hoffman ALS Clinical Trial Awards - Health Research Alliance Benefits of HRA Membership HRA Member Organization Profiles HRA Member Organization Directory (Members-Only) Individual Member Directory (Members-Only) AI and Large Language Models (LLM) Diversity Equity Inclusion Inclusive Grantmaking Initiative (IGI) Exploring the Value of “Open” (EVO) Program Registry and Biorepository Community Research Workforce & Early Career Development Communications (inactive) Funder-Institution RelationS Task (FIRST) Group (inactive) NFRI Intellectual Property and Tech Transfer Workgroup (inactive) NFRI Research Project Support Costs Workgroup (inactive) NFRI Streamlining Administrative Requirements Workgroup (inactive) Health Services Research (inactive) Bias Mitigation in Peer Review Training Grants Administration Handbook Clinical Trials Interest Group (inactive) Deadline Extended: Hoffman ALS Clinical Trial Awards Home Page › Forums › RFA/RFP › Deadline Extended: Hoffman ALS Clinical Trial Awards This topic has 0 replies, 1 voice, and was last updated 10 months, 3 weeks ago by Kiley Goldstein .

Viewing 1 post (of 1 total) October 22, 2025 at 1:48 pm Good Morning Fellow HRA Members! The ALS Association has extended the deadline for our 2026 Hoffman ALS Clinical Trial Awards . Letters of intent are now due Tuesday, November 18, 2025, 1 p.

m. US ET. This program supports early- to mid-stage (phase 1 or 2a) biomarker-driven clinical trials of novel or repurposed therapeutics for ALS (either disease-modifying or symptomatic).

Early trials testing imaging tracers are also in scope. Both industry and academic investigators are eligible to apply. Successful applications will: Include a clear and compelling biological rationale for the target biology and pathway.

Include a robust preclinical data package providing the rationale for the proposed treatment/tracer moving to the clinical stage. Have an integrated biomarkers program that uses robust, reliable, replicable, and reproducible assays with clearly defined contexts of use. Propose outcomes that are aligned with the trial phase.

Provide a clear plan, including “go/no-go” decision milestones, for moving the approach through the essential stages of clinical development. Describe what additional funding sources are in hand already or will be pursued to fund the entire trial (e.g., government, private/VC investors, industry partnerships, etc.). For a list of previously funded projects, please visit our website .

Funding and Award Information Funding Amount: Up to $1,000,000 (inclusive of both direct and indirect costs) Grant Duration: 2 or 3 years Indirect Costs: Limited to 10% of total direct costs when PI salary is waived Letter of Intent Due: November 18, 2025, 1 p. m. US ET Full Proposal Due (by invitation only): February 17, 2026, 1 p.

m. US ET Anticipated Award Decision: May 2026 Anticipated Earliest Start Date: July 1, 2026 We would appreciate any help in spreading the word to your networks! Click here for more information and submission guidelines.

If you have any questions, please email [email protected] . The ALS Association Research Team Viewing 1 post (of 1 total) You must be logged in to reply to this topic.